Company profile
COMPUGEN LTD
NASDAQ:CGENBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| COM-701 | phase1_2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06759649 | phase1 | recruiting | 2025-01-07 | 2027-11-22 | Compugen Ltd | A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies |
| NCT06888921 | phase1_2 | active_not_recruiting | 2025-07-21 | 2027-03-01 | Compugen Ltd | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer |
| NCT03667716 | phase1 | completed | 2018-09-06 | 2024-01-30 | Compugen Ltd | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. |
| NCT04570839 | phase1_2 | completed | 2020-08-31 | 2024-05-15 | Compugen Ltd | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. |
| NCT04354246 | phase1 | completed | 2020-03-31 | 2026-04-01 | Compugen Ltd | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies |
FDA applications (0)
No records yet.